Rosuvastatin-Based Lipid-Lowering Therapy for the Control of LDL Cholesterol in Patients at High Vascular Risk

Area of Science:

• Cardiology
• Pharmacology

Background:

• Vascular diseases are the primary cause of mortality in Spain.
• Hypercholesterolemia is a key risk factor for atherosclerosis and cardiovascular events.
• Current low-density lipoprotein cholesterol (LDL-C) control remains inadequate, particularly in high-risk individuals.

Purpose of the Study:

• To highlight the importance of achieving guideline-recommended LDL-C goals.
• To emphasize the need for intensified lipid-lowering therapy.
• To present rosuvastatin, alone or with ezetimibe, as an effective therapeutic option.

Main Methods:

• Review of clinical practice guidelines for hypercholesterolemia management.
• Analysis of the efficacy of rosuvastatin and rosuvastatin/ezetimibe combinations.
• Assessment of LDL-C reduction percentages and side effect profiles.

Main Results:

• Rosuvastatin achieves LDL-C reductions of 50-55%.
• Combination therapy with rosuvastatin and ezetimibe yields 60-75% LDL-C reduction.
• These therapies demonstrate a favorable safety profile and efficiency.

Conclusions:

• Intensified lipid-lowering treatment is essential for managing hypercholesterolemia and preventing vascular complications.
• Rosuvastatin, with or without ezetimibe, provides effective and well-tolerated LDL-C lowering for diverse patient populations.
• Tailoring therapy based on individual LDL-C levels and vascular risk is critical for optimal outcomes.